| P50 | author | Juha Sinisalo | Q37389883 |
| P2093 | author name string | Petri T Kovanen | |
| | Kari K Eklund | |
| | Jukka Lehtonen | |
| | Otto Hartman | |
| P2860 | cites work | Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland | Q41401856 |
| | The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial | Q41917902 |
| | Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism | Q41921412 |
| | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications | Q41921823 |
| | Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 |
| | Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis | Q41932479 |
| | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 |
| | Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients | Q41933182 |
| | Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus | Q41936831 |
| | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 |
| | Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | Q41943988 |
| | Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes | Q41946037 |
| | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials | Q57630066 |
| | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease | Q28548561 |
| | Inflammation, atherosclerosis, and coronary artery disease | Q29547232 |
| | Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 |
| | NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 |
| | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q29620108 |
| | Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation | Q33644572 |
| | ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). | Q34212424 |
| | Third universal definition of myocardial infarction | Q34295914 |
| | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases | Q34354276 |
| | Cytokines in atherosclerosis: pathogenic and regulatory pathways | Q34511711 |
| | Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 |
| | Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial | Q36073241 |
| | Cohort Profile: the Corogene study | Q36301931 |
| | Toll-like Receptors in the Vascular System: Sensing the Dangers Within | Q36453194 |
| | Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 |
| | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients | Q36877859 |
| | Pleiotropic effects of statins. - Basic research and clinical perspectives -. | Q37252114 |
| | Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 |
| | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 |
| | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects | Q38029146 |
| | Mechanisms of acute coronary syndromes and their implications for therapy | Q38108628 |
| | Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation | Q38337969 |
| | Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial | Q38394069 |
| | Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 |
| | Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial | Q38441000 |
| | The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 |
| | Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study | Q39144641 |
| | Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines | Q39577031 |
| P433 | issue | 2 | |
| P921 | main subject | myocardial infarction | Q12152 |
| | hydroxychloroquine | Q421094 |
| P304 | page(s) | 92-97 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | European heart journal. Cardiovascular pharmacotherapy | Q27726932 |
| P1476 | title | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. | |
| P478 | volume | 3 | |